Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809)

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 10, 2015, Pages 2469-2474

  McNeel, Douglas G ^a   Chen, Yu Hui ^b   Gulley, James L ^c   Dwyer, Alexander J ^a   Madan, Ravi A ^c   Carducci, Michael A ^d   Dipaola, Robert S ^e  

^a UNIVERSITY OF WISCONSIN   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

Docetaxel; Phase II clinical trial; Prostate cancer; Vaccine

Indexed keywords

BIOLOGICAL MARKER; DOCETAXEL; GAMMA INTERFERON; HLA A2 ANTIGEN; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; PREDNISONE; RILIMOGENE GALVACIREPVEC; TUMOR NECROSIS FACTOR ALPHA; TUMOR VACCINE; VIRUS VECTOR; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; CANCER VACCINE; PROSTATE SPECIFIC ANTIGEN; TAXOID;

ANTIBODY RESPONSE; ARTICLE; BLOOD ANALYSIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNIZATION; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ASSESSMENT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FOLLOW UP; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; AGED; BLOOD; CLINICAL TRIAL; IMMUNOLOGY; MIDDLE AGED; NEOPLASM METASTASIS; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

AGED; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 84953865143     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1062190     Document Type: Article

References (31)

1. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, et al. Docetaxel and estramustine com- pared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351:1513-20; PMID:15470214; http://dx.doi.org/10.1056/NEJMoa041318
2. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Tures-son I, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-12; PMID:15470213; http://dx.doi.org/10.1056/NEJMoa040720
3. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al. Sipuleucel-T immunotherapy for cas- tration-resistant prostate cancer. N Engl J Med 2010; 363:411-22; PMID:20818862; http://dx.doi.org/10.1056/NEJMoa1001294
4. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364:1995-2005; PMID:21612468; http://dx.doi.org/10.1056/NEJMoa1014618
5. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367:1187-97; PMID:22894553; http://dx.doi.org/10.1056/NEJMoa1207506
6. Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Seke M, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369:213-23; PMID:23863050; http://dx.doi.org/10.1056/NEJMoa1213755
7. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, et al. Prednisone plus cabazitaxel or mitox-antrone for metastatic castration-resistant prostate can- cer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376:1147-54; PMID:20888992; http://dx.doi.org/10.1016/S0140-6736(10)61389-X
8. Sweeney CJ, Chen YH, Carducci MA, Liu G, Jarrard DF, Eisenberger MA, Wong Y-N, Hahn NM, Kohli M, Vogelzang NJ, et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): an ECOG-led phase III randomized trial. J Clin Oncol 2014; 32:5s (suppl; abstr LBA2); http://dx.doi.org/10.1200/JCO.2013.49.4757
9. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N, Frohlich MW. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115:3670-9; PMID:19536890; http://dx.doi.org/10.1002/cncr.24429
10. Gulley J, Chen AP, Dahut W, Arlen PM, Bastian A, Steinberg SM, Tsang K, Panicali D, Poole D, Schlom J, et al. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 2002; 53:109-17; PMID:12242725; http://dx.doi.org/10.1002/pros.10130
11. Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J, Gritz L, Mazzara G, Oh WK, Arlen P, et al. 2474 A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 2000; 6:1632-8; PMID:10815880
12. Sanda MG, Smith DC, Charles LG, Hwang C, Pienta KJ, Schlom J, Milenic D, Panicali D, Montie JE. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology 1999; 53:260-6; PMID:9933036; http://dx.doi.org/10.1016/S0090-4295(98)00539-1
13. Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P, Tsang KY, Yokokawa J, Hodge JW, Menard C, et al. Combining a recombinant cancer vac-cine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005; 11:3353-62; PMID:15867235; http://dx.doi.org/10.1158/1078-0432.CCR-04-2062
14. Schuetz T, Marshall J, Kaufman H, Safran H, Panicali D. Two phase I studies of prime-boost vaccinations with vaccinia-fowlpox vaccines expressing CEA, MUC-1, and TRICOM costimulatory mole- cules (B7.1/ICAM-1/LFA-3) in patients with advanced pancreatic cancer. J Clin Oncol 2004; 22 (14S):2564
15. Arlen PM, Gulley J, Dahut W, Skarupa L, Morin S, Pazdur M, Todd N, Panicali D, Tsang KY, Schlom J. A phase I study of sequential vaccinations with recombinant Fowlpox-PSA (L155)-TRICOM (rF) alone, or in combination with recombinant vaccinia-PSA (L155)-TRICOM (rV), and the role of GM-CSF, in patients (Pts) with prostate cancer. J Clin Oncol 2004; 22(14S):2522; PMID:15173215
16. Arlen PM, Skarupa L, Pazdur M, Seetharam M, Tsang KY, Grosenbach DW, Feldman J, Poole DJ, Litzinger M, Stei nberg SM, et al. Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol 2007; 178:1515-20; PMID:17707059; http://dx.doi.org/10.1016/j.juro.2007.05.117
17. Essajee S, Kaufman HL. Poxvirus vaccines for cancer and HIV therapy. Expert Opin Biol Ther 2004; 4:575-88; PMID:15102606; http://dx.doi.org/10.1517/14712598.4.4.575
18. Bernards R, Destree A, McKenzie S, Gordon E, Weinberg RA, Panicali D. Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector. Proc Natl Acad Sci USA 1987; 84:6854-8; PMID:3477812; http://dx.doi.org/10.1073/pnas.84.19.6854
19. Irvine K, Kantor J, Schlom J. Comparison of a CEA-recombinant vaccinia virus, purified CEA, and an anti-idiotypic antibody bearing the image of a CEA epitope in the treatment and prevention of CEA-expressing tumors. Vaccine Res 1993; 2:79-94
20. Kass E, Schlom J, Thompson J, Guadagni F, Graziano P, Greiner JW. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res 1999; 59:676-83; PMID:9973217
21. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, God-rey WR. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Onc 2010; 28(7): 1099-1105.
22. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003; 21:1232-7; MID:12663709; http://dx.doi.org/10.1200/JCO.2003.06.100
23. Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, Jones JL, Poole DJ, Higgins JP, Hodge JW, et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 2010; 59:663-74; PMID:19890632; http://dx.doi.org/10.1007/s00262-009-0782-8
24. Antonia SJ, Mirza N, Fricke I, Chiappori A, Thomp-son P, Williams N, Bepler G, Simon G, Janssen W, Lee JH, et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 2006; 12:878-87; PMID:16467102; http://dx.doi.org/10.1158/1078-0432.CCR-05-2013
25. Petrylak D. Defiing the optimal role of immunotherapy and chemotherapy: advanced prostate cancer patients who receive Sipuleucel-T (PROVENGE) followed by docetaxel derive the greatest survival benefit. 14th Annual Meeting of the Chemotherapy Foundation Symposium. New York, NY, 2006.
26. Small EJ, Sacks N, Nemunaitis J, Urba WJ, Dula E, Centeno AS, Nelson WG, Ando D, Howard C, Borellini F, et al. Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 2007; 13:3883-91; PMID:17606721; http://dx.doi.org/10.1158/1078-0432.CCR-06-2937
27. Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D, Beetham P, Tsang KY, Grosenbach DW, Feldman J, et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 2006; 12:1260-9; PMID:16489082; http://dx.doi.org/10.1158/1078-432.CCR-05-2059
28. Dipaola R, Plante M, Kaufman H, Petrylak D, Israeli R, Lattime E, Manson K, Schuetz T. A Phase I Trial of Pox PSA vaccines (PROSTVAC(R)-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRI-COMtrade mark) in Patients with Prostate Cancer. J Trans Med 2006; 4:1; PMID:16390546; http://dx.doi.org/10.1186/1479-5876-4-1
29. McNeel DG, Becker JT, Eickhoff JC, Johnson LE, Bradley E, Pohlkamp I, Staab MJ, Liu G, Wilding G, Olson BM. Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer. Clin Cancer Res 2014; 20:3692-704; PMID:24850844; http://dx.doi.org/10.1158/1078-0432.CCR-14-0169
30. Gulley JL, Madan RA, Tsang KY, Jochems C, Marte JL, Farsaci B, Tucker JA, Hodge JW, Liewehr DJ, Steinberg SM, et al. Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. Cancer Immunol Res 2014; 2:133-41; PMID:24778277; http://dx.doi.org/10.1158/ 2326-6066.CIR-13-0108
31. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122-33; PMID:23724867; http://dx.doi.org/10.1056/NEJMoa1302369